|
|
T2 Biosystems Announces Third Quarter 2024 Financial Results
|
|
|
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
|
|
|
T2 Biosystems to Host Business Update Call on October 10, 2024
|
|
|
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
|
|
|
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
|
|
|
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
|
|
|
T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
|
|
|
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
|
|
|
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
|
|
|
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
|
